Marken Opens New Philadelphia Hub
News May 16, 2015
Marken has announced the opening of its newest office and warehouse in Philadelphia. The hub is the newest addition to Marken’s global drug distribution network, comprised of 10 cGMP compliant depots and more than 40 locations around the world.
The new Philadelphia facility is designed to enable the distribution of clinical trial supplies within all temperature ranges for clients with manufacturing or packaging facilities in Pennsylvania and New Jersey.
Dedicated features of this new 8865 square foot facility include a large 15 to 25ºC controlled room temperature area, a 2 to 8ºC walk in refrigerator and a -20ºC freezer. The rooms are equipped with a 24/7 temperature monitoring system, fully mapped and calibrated.
“The new Philadelphia location is an excellent addition to our worldwide network of depots and logistics facilities. It will provide easy access to our local clients and enhance our global drug distribution services by offering clients a full service staging and distribution solution in Philadelphia,” says Mark Hembarsky, Marken’s Vice President of Logistics for North America.
“The facility has been built to Marken’s exact specifications and will be operated under strict security with constant temperature controls. This new hub will operate like all Marken facilities, using Maestro for shipment bookings and tracking worldwide,” he adds.
Marken will host a grand opening event on Wednesday, May 27, 2015 in downtown Philadelphia for local clients. The dinner event will feature a key note presentation from an industry expert. Attendees will also have the opportunity to network and learn more about Marken’s clinical trial logistics solutions, flexible depot network and other value added services.
With 35 years of experience and 100% dedication to the life sciences industry, Marken will continue to expand its global presence to support the increase in size and complexity of the drug distribution market.
Advanced Prostate Cancer: EMA Approves Abiraterone Combined With Hormone Therapy as First-line TreatmentNews
The prostate cancer drug abiraterone has been approved by the European Medicines Agency in combination with standard hormone therapy for use as a first-line treatment for advanced prostate cancer.READ MORE
Diabetes Drug Could Be Re-purposed to Help End Transplant RejectionNews
A diabetes drug currently undergoing development could be repurposed to help end transplant rejection, without the side-effects of current immunosuppressive drugs.READ MORE
Study Shows Cancer Patients Are Choosing Less Severe Side Effects Over Treatment EfficacyNews
When choosing their preferred treatment, people with chronic lymphocytic leukemia (CLL) place the highest value on medicines that deliver the longest progression-free survival, but are willing to swap some drug efficacy for a reduced risk of serious adverse events according to a new study.READ MORE